Role change
Tony J. Hunt
Executive Chair
RGEN ·
REPLIGEN CORP
Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors
Ready 8-Ks
21
Latest filing
May 15, 2026, 8:09 AM ET
Top materiality
0.80
Event mix
earnings ×10 · leadership ×5 · other_material ×3
Sentiment
8 pos · 3 neg · 10 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for RGEN
Highest-materiality recent filing
Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M
- Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
- Q4 GAAP EPS $0.23 vs ($0.60); adjusted EPS $0.49 vs $0.44. Full year adjusted EPS $1.71 vs $1.58.
-
Repligen 2026 annual meeting: all proposals pass; director Muir gets 25.7% against
All nine director nominees elected; Glenn P. Muir received highest opposition (13.3M against, 25.7% of votes cast).
-
Repligen Q1 revenue $194M (+11% organic); raises adjusted EPS guidance to $1.97-$2.05
Q1 revenue $194M, +15% reported/+11% organic; GAAP EPS $0.15, adjusted EPS $0.48 (+23% YoY).
-
Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M
Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
-
Repligen elects Martin D. Madaus as Chair, succeeding Tony Hunt effective Mar 13, 2026
Tony Hunt retires as Executive Chair and Board member effective March 13, 2026; will serve as advisor through March 2027.
-
Repligen Q3 revenue $189M (+22% YoY); raises FY2025 guidance to $729-737M
Revenue $189M, +22% reported, +18% organic; double-digit growth across all franchises.
-
Repligen appoints Violetta Hughes as Chief Accounting Officer, effective Sept 1, 2025
Replaces Jason K. Garland as principal accounting officer; Garland remains CFO focusing on strategy.
-
Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance
Revenue $182M, up 15% reported and 17% organic non-COVID YoY.
-
Stockholders approved a Certificate of Amendment to limit officer liability under Delaware law (45.3M for, 5.9M against).
-
Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens
Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
-
Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth
Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
-
Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23
GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
-
Restatement covers Q1'23 through Q2'24; $17.3M payment from cancelled COVID orders was mis-timed.
-
Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition
Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
-
Repligen reports unauthorized access to files on its information systems
Unauthorized third party accessed certain files on July 9, 2024; response procedures activated immediately.
-
Repligen appoints Olivier Loeillot as CEO effective Sept 1, 2024; Hunt becomes Executive Chair
Loeillot receives $750K base salary, 85% target bonus, and a $5M equity award (50% RSUs, 25% options, 25% PSUs).
-
Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
-
Repligen shareholders elect all nine directors, ratify EY, approve say-on-pay at 2024 meeting
All nine director nominees elected with votes for ranging from ~45.95M to ~49.48M.
-
Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28
Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).
-
Repligen appoints Maggie A. Pax to Board of Directors, expanding to nine members
Pax elected to board effective March 18, 2024; board expands from eight to nine members.
-
Repligen Q4 revenue down 16.6% to $155.7M; net loss $0.46/share
Q4 2023 revenue $155.7M vs $186.8M in Q4 2022; full year $638.8M vs $801.5M.
-
Repligen issues $600M of 1.00% convertible notes due 2028, exchanges ~$310M of 2024 notes
Issued $600M aggregate principal of 1.00% Convertible Senior Notes due 2028, with ~$309.9M exchanged for existing 0.375% 2024 notes and ~$290.1M cash.
Executive changes
Appointed
Olivier Loeillot
President and Chief Executive Officer
RGEN ·
REPLIGEN CORP
Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024
Role change
Karen A. Dawes
Lead Independent Director
RGEN ·
REPLIGEN CORP
appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director
Appointed
Olivier Loeillot
Member of the Board
RGEN ·
REPLIGEN CORP
the Board elected Mr. Loeillot as a member of the Board
Appointed
Margaret A. Pax
Director
RGEN ·
REPLIGEN CORP
the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.70 · Most common event earnings